Skip to content

Effects of Low-Dose Dexmedetomidine Nasal Preadministration on Perioperative Hemodynamic Stability, Postoperative Shivering, Nausea and Vomiting, and the Incidence of Postpartum Depression in Parturients Undergoing Cesarean Section

Effects of Low-Dose Dexmedetomidine Nasal Preadministration on Perioperative Hemodynamics, Shivering, Vomiting, and Postpartum Depression in Parturients Undergoing Cesarean Section

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109021
Enrollment
Unknown
Registered
2025-09-10
Start date
2025-09-10
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Dex group:Prior to the cesarean section, dexmedetomidine at a dose of 0.5 µg/kg was administered via preemptive intranasal instillation.
Blank group:Prior to a cesarean section, the same volume of saline (dexmedetomidine 0.5ug/kg) was pre-nasal dropped.

Sponsors

Maternal and Child Health Hospital of Hubei Province
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.Parturients undergoing cesarean section under spinal anesthesia; 2.18~45 years old; 3.ASAII; 4.Full-term pregnancy; 5.18.5=10; 8.Puerpera could communicate well with the follow-up, understand the trial process, voluntarily participate in the study and sign the relevant informed consent.

Exclusion criteria

Exclusion criteria: 1.Allergy to a2-agonists; 2.Preoperative placenta previa, placental abruption and other diseases with estimated blood loss greater than 800 ml; 3.Preoperative sinus bradycardia (maternal heart rate less than 50 beats/min), or cardiac conduction or sick sinus syndrome abnormal cardiac rhythm diseases; 4.Preoperative hypotension (defined as systolic blood pressure < 90mmHg and/or diastolic blood pressure < 60mmHg); 5.Patients with unstable mental disorders or depressive disorders; 6.History of psychotropic drugs and alcohol abuse; 7.Long-term use of a drug within 6 months before the study; 8.Participating in other clinical drug trials during the same period; 9.Unable to understand the language of the follow-up, unable to communicate well; 10.Cases deemed unsuitable for collection by the investigators.

Design outcomes

Primary

MeasureTime frame
Visual pain score;Apgar score;Edinburgh Postnatal Depression Scale (EPDS) Score;Heart rate;Blood presure;Oxygen saturation;Perioperative adverse reactions;

Secondary

MeasureTime frame
Degree of satisfaction;The volume of blood loss during childbirth;

Countries

China

Contacts

Public ContactWei Yan

Hubei Maternal and Child Health Hospital

15927124927@163.com+86 159 2712 4927

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026